For instance, extensive research has focused on the utilization of DNA methyltransferase inhibitors (DNMTis), histone acetyltransferase inhibitors, histone deacetylase inhibitors, histone methyltransferase inhibitors, and bromodomain and extra-terminal (BET) inhibitors as potential treatment options for inflammation and coronary artery disease (CAD). This evidence concerns the gene PRDM9 and coronary artery disorder.